NEW YORK (GenomeWeb News) – Sequenta said today it has received CLIA certification for a clinical test based on in its immune repertoire sequencing-based technology called LymphoSight.

"Full clonality analysis of immune cell repertoires will have applications in the diagnosis and management of many blood cancers," Sequenta CEO Tom Willis said in a statement. "With CLIA certification, we are now able to use the LymphoSight method and make these clinical tests available to the physician community."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.

Feb
21
Sponsored by
Oracle Health Sciences

This webinar will cover best practices for integrating data from multiple clinical and genomic sources for clinical decision support.